Caption Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caption Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Sell	21,400 -33,900	-61%	-$1.86M	0.01%	1061
2026 Q1	$3.12M	Buy	55,300 +35,800	+184%	+$2.09M	0.02%	682
2025 Q4	$1.16M	Buy	+19,500	New	+$1.06M	0.01%	1008
2024 Q4	–	Sell	-27,300	Closed	-$1.83M	–	1470
2024 Q3	$1.92M	Buy	+27,300	New	+$2.28M	0.03%	572
2024 Q2	–	Sell	-22,929	Closed	-$1.91M	–	1172
2024 Q1	$2M	Buy	22,929 +9,649	+73%	+$864K	0.03%	531
2023 Q4	$1.28M	Buy	+13,280	New	+$1.17M	0.02%	744
2023 Q3	–	Sell	-113,872	Closed	-$10.1M	–	1283
2023 Q2	$9.87M	Buy	113,872 +83,872	+280%	+$7.89M	0.17%	144
2023 Q1	$2.92M	Buy	+30,000	New	+$3.11M	0.06%	355
2022 Q3	–	Sell	-19,495	Closed	-$1.74M	–	1504
2022 Q2	$1.62M	Buy	19,495 +3,090	+19%	+$246K	0.02%	729
2022 Q1	$1.26M	Buy	+16,405	New	+$1.37M	0.02%	886
2021 Q2	–	Sell	-25,399	Closed	-$1.92M	–	1308
2021 Q1	$1.92M	Buy	25,399 +24,997	+6,218%	+$2.04M	0.04%	526
2020 Q4	$35K	Sell	402 -29,898	-99%	-$2.37M	﹤0.01%	917
2020 Q3	$2.31M	Sell	30,300 -36,688	-55%	-$3.71M	0.05%	390
2020 Q2	$8.26M	Buy	+66,988	New	+$6.66M	0.28%	84
2019 Q4	–	Sell	-4,000	Closed	-$302K	–	828
2019 Q3	$269K	Sell	4,000 -12,500	-76%	-$963K	0.01%	560
2019 Q2	$1.41M	Sell	16,500 -6,100	-27%	-$522K	0.07%	308
2019 Q1	$2.01M	Buy	+22,600	New	+$2.09M	0.11%	239
2018 Q1	–	Sell	-25,000	Closed	-$2.15M	–	226
2017 Q4	$2.23M	Buy	+25,000	New	+$2.17M	0.23%	125

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Caption Management's BMRN Position: Q2 2026 in Review

Caption Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 61% in Q2 2026, selling an estimated $1.86M and leaving 21,400 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #1061.

Caption Management first reported a position in BMRN in Q4 2017 and has held it in 18 quarters since. The position peaked at $9.87M in Q2 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Caption Management held 21,400 shares of BioMarin Pharmaceuticals worth $1.22M as of Q2 2026.
Caption Management sold 33,900 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.86M.
BioMarin Pharmaceuticals made up 0.01% of Caption Management's portfolio in Q2 2026, its #1061 holding.
Caption Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
Caption Management's BioMarin Pharmaceuticals position peaked at $9.87M in Q2 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.